SPRY

ARS Pharmaceuticals Inc

3.38

Oct 30 • 3:59 PM ET -0.28 (-7.65%)

3.32

Aftermarket • 7:30 PM ET -0.06 (-1.73%)

Healthcare Biotechnology USA Small NASD

Peers: AQST DBVT VTRS AMRX AMPH PHAR TEVA APMD REGN NVS

| Held by: XBI VTI IWM VXF IWO IBB VTWO SCHA VHT LABU

Scroll to Statements

Index	RUT
Market Cap	336.13M
Enterprise Value	288.97M
Income	-215.43M
Sales	116.93M
Book/sh	0.13
Cash/sh	1.45
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	163
IPO	Dec 04, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	2.87
P/B	26.86
P/C	2.34
P/FCF	-
EV/EBITDA	-
EV/Sales	2.47
Quick Ratio	3.28
Current Ratio	3.48
Debt/Eq	7.73
LT Debt/Eq	7.73
Option/Short	Yes / Yes

EPS (ttm)	-2.17
EPS next Y	-0.81
EPS next Q	-0.30
EPS this Y	-2.59%
EPS next Y	54.34%
EPS next 5Y	88.35%
EPS past 3/5Y	-26.04% -12.85%
Sales past 3/5Y	300.09% -
EPS Y/Y TTM	-343.67%
Sales Y/Y TTM	4.08%
EPS Q/Q	-37.56%
Sales Q/Q	114.15%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	-31.88% 7.46%

Insider Own	34.38%
Insider Trans	-0.08%
Inst Own	71.60%
Inst Trans	-4.60%
ROA	-76.53%
ROE	-210.35%
ROIC	-197.30%
Gross Margin	71.37%
Oper. Margin	-184.96%
Profit Margin	-184.24%
SMA20	-16.93%
SMA50	-26.09%
SMA200	-54.28%
Trades

Shs Outstand	99.44M
Shs Float	65.25M
Short Float	30.38%
Short Ratio	11.98
Short Interest	19.82M
52W High	13.15 -74.30%
52W Low	3.53 -4.11%
Volatility	8.05% 6.83%
ATR (14)	0.28
RSI (14)	29.78
Beta	0.94
Rel Volume	1.06
Avg Volume	1.65M
Volume	1,756,636

Perf Week	-16.13%
Perf Month	-17.96%
Perf Quarter	-38.10%
Perf Half Y	-60.51%
Perf YTD	-70.99%
Perf Year	-60.79%
Perf 3Y	-2.87%
Perf 5Y	-60.83%
Perf 10Y	-
Recom	1.00
Target Price	24.33
Prev Close	3.66
Price	3.38
Change %	-7.65%

Consensus

Strong Buy

Avg. Price Target

$24.33

Implied Upside

+619.8%

Analysts10incl. previous ratings

Rating Distribution10 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Apr 09, 2026	Initiated	NNorthland Capital	Outperform	$25	+639.6%
Nov 04, 2025	Resumed	RRoth Capital	Buy	$30	+787.6%
Sep 04, 2025	Initiated	RRoth Capital	Buy	$40	+1,083.4%
Mar 07, 2025	Initiated	BScotiabank	Sector Outperform	$30	+787.6%
Feb 10, 2025	Initiated	OOppenheimer	Outperform	$40	+1,083.4%
Aug 20, 2024	Initiated	CCantor Fitzgerald	Overweight
Aug 13, 2024	Upgrade	RRaymond James	Outperform → Strong Buy	$18 → $22	+550.9%
Aug 12, 2024	Reiterated	LLeerink Partners	Outperform	$19 → $20	+491.7%
Jul 25, 2024	Initiated	RRaymond James	Outperform	$18	+432.5%
Mar 05, 2024	Upgrade	LLeerink Partners	Market Perform → Outperform	$6 → $18	+432.5%
Feb 20, 2024	Upgrade	WWilliam Blair	Mkt Perform → Outperform
Sep 20, 2023	Downgrade	WWilliam Blair	Outperform → Mkt Perform
Jan 31, 2023	Initiated	WWedbush	Outperform	$10	+195.9%
Jan 03, 2023	Initiated	WWilliam Blair	Outperform	$17	+403.0%
Dec 13, 2022	Initiated	SSVB Leerink	Outperform	$14	+314.2%

Oct-28-26 09:54PM	ARS Pharmaceuticals Faces Proof Test As Cost Cuts Meet A Lofty Revenue Bar (Earnings Whispers)
04:01PM	ARS Pharma to Report Third Quarter 2026 Financial Results (GlobeNewswire)
Oct-05-26 03:28AM	ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY (PR Newswire) +5.41%
Sep-28-26 04:12AM	ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY (PR Newswire)
Sep-16-26 10:50AM	Kaplan Fox Urges ARS Pharmaceuticals Inc. (SPRY) Investors Seeking Recovery to Contact the Firm Before October 5, 2026 (Newsfile)
04:01PM	Loading…
Sep-01-26 04:01PM	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-31-26 03:12AM	ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY (PR Newswire)
Aug-24-26 09:35AM	Kaplan Fox Encourages ARS Pharmaceuticals Inc. (SPRY) Investors with Losses to Contact the Firm Before October 5, 2026 (Newsfile)
Aug-17-26 11:45AM	Kaplan Fox Urges Investors of ARS Pharmaceuticals Inc. (SPRY) with Significant Losses to Seek a Leadership Role Before October 5, 2026 (Newsfile) +10.44%
Aug-14-26 01:02AM	ARS Pharmaceuticals Inc (SPRY) (Q2 2026) Earnings Call Highlights: Market Share Doubles to 5% ... (GuruFocus.com) -7.38%
Aug-13-26 04:01PM	ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results (GlobeNewswire)
01:18PM	Did You Lose Money Investing in ARS Pharmaceuticals Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against SPRY (Newsfile)
Aug-12-26 03:00PM	Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (SPRY) Who Suffered Losses to Contact the Firm Before October 5, 2026 (Newsfile)
09:24AM	What To Expect From ARS Pharmaceuticals Inc (SPRY) Q2 2026 Earnings (GuruFocus.com)
Aug-10-26 07:30AM	ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights SPRY (Business Wire)
07:30AM	Loading…
Aug-03-26 07:30AM	ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results (GlobeNewswire) +6.43%
Jul-07-26 04:30PM	ARS Pharmaceuticals Announces CEO Succession (GlobeNewswire)
Jun-25-26 10:42AM	Micron Sparks Fresh AI Stock Rally (GuruFocus.com) -23.91%
10:08AM	ARS Pharma Collapses After CVS Punts Its Epinephrine Spray Decision To January (Investor's Business Daily)
Jun-24-26 09:43PM	SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today (Stocktwits)
08:09PM	SPRY Stock Tanks Over 23% After-Hours ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy (Stocktwits)
04:05PM	ARS Pharmaceuticals Provides Commercial and Financial Updates (GlobeNewswire)
Jun-04-26 08:00AM	Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies (GlobeNewswire)
May-15-26 07:01PM	ARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) -6.49%
06:00AM	ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
May-13-26 08:00AM	ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President (GlobeNewswire) -7.18%
May-07-26 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results (GlobeNewswire)
Apr-15-26 06:05AM	neffy (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Mar-27-26 08:00AM	ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy 1 mg (epinephrine nasal spray) Label (GlobeNewswire) -5.72%
Mar-09-26 03:01PM	ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings Call Highlights: Strong Market Entry and ... (GuruFocus.com)
07:10AM	Loading…
07:10AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
06:00AM	ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) Commercialization (GlobeNewswire)
Mar-06-26 07:15AM	What To Expect From ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings (GuruFocus.com)
Mar-02-26 12:23PM	Canadian Natural to Report Q4 Earnings: What's in the Offing? (Zacks)
10:00AM	ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-23-26 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences (GlobeNewswire)
Feb-10-26 08:00AM	ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting (GlobeNewswire)
Feb-02-26 01:12PM	What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment? (Benzinga)
Jan-21-26 08:00AM	California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use (GlobeNewswire)
Jan-09-26 12:32PM	Bad News For Competitor Turns Into Big Win For ARS Pharma Stock (Benzinga) +19.27%
11:28AM	Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application (Benzinga)
03:16AM	ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating (Insider Monkey)
Dec-30-25 08:10AM	ARS Pharmaceuticals announces NMPA approval for neffy 2 mg (TipRanks)
Dec-29-25 08:00AM	neffy (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Nov-26-25 08:00AM	ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-10-25 04:01PM	ARS Pharmaceuticals Inc (SPRY) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
07:05AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
06:00AM	ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy (epinephrine nasal spray) (GlobeNewswire)
Nov-07-25 07:19AM	ARS Pharmaceuticals Inc (SPRY) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com) +7.99%
Nov-06-25 09:10AM	Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -9.45%
Nov-05-25 09:15AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-04-25 09:35AM	DraftKings, Flutter downgraded: Wall Street's top analyst calls (The Fly)
08:00AM	ARS Pharma Launches Get neffy on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray) (GlobeNewswire)
Nov-03-25 02:23PM	UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results (GlobeNewswire)
07:45AM	ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
Oct-08-25 08:00AM	ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy (epinephrine nasal spray) (GlobeNewswire) +7.55%
Sep-29-25 04:05PM	ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy (GlobeNewswire)
Sep-19-25 08:00AM	neffy (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Sep-17-25 11:44AM	ARS Pharmaceuticals, Inc. (SPRY): A Bull Case Theory (Insider Monkey)
Sep-09-25 08:11AM	ARS Pharmaceuticals announces real-world evidence on neffy effectiveness (TipRanks)
Sep-08-25 08:00AM	Real-World Evidence Supports Clinical Effectiveness of neffy (epinephrine nasal spray) in Patients Experiencing Anaphylaxis (GlobeNewswire) +6.26%
Sep-04-25 02:54PM	ARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDA (Insider Monkey)
Aug-28-25 08:00AM	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-25 08:15AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -5.04%
07:00AM	ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy (epinephrine nasal spray) (GlobeNewswire)
05:26AM	Cisco Systems headlines earnings slate (MarketWatch)
Aug-12-25 09:24AM	ARS Pharmaceuticals Inc (SPRY) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Aug-11-25 06:55PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -6.40%
Aug-08-25 01:56PM	Paramount, Rocket, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-04-25 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 05:35PM	Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates (Zacks)
08:50AM	Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength (Zacks)
Jul-30-25 10:00AM	Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-29-25 10:00AM	Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-18-25 12:27PM	MHRA approves needle-free adrenaline nasal spray for anaphylaxis (Pharmaceutical Technology)
09:25AM	EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Jul-15-25 12:00PM	ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy? (Zacks)
09:55AM	Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High? (Zacks)
08:50AM	What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing' (Zacks)
Jun-15-25 05:26AM	Jim Cramer on ARS Pharmaceuticals: "It's a Great Flier" (Insider Monkey)
Jun-11-25 09:02PM	Lightning Round: I don't want to buy enterprise software right now, says Jim Cramer (CNBC TV)
May-27-25 08:00AM	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-15-25 03:12AM	ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Call Highlights: Strong Launch of Neffy Amid ... (GuruFocus.com)
May-14-25 10:44PM	Q1 2025 ARS Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -9.36%
08:15AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy (epinephrine nasal spray) (GlobeNewswire)
May-13-25 09:28AM	ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-08-25 05:06AM	ARS Pharmas epinephrine nasal spray 1mg now available in US (Pharmaceutical Technology)
May-05-25 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results (GlobeNewswire)
May-04-25 04:32PM	Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential (Seeking Alpha)
May-02-25 08:00AM	ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abello A/S to Expand Reach of neffy (epinephrine nasal spray) to Additional U.S. Pediatricians (GlobeNewswire)
Apr-30-25 06:51AM	ARS Pharmaceuticals Has A Blockbuster Candidate (Seeking Alpha)
Apr-05-25 05:31PM	ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money (Insider Monkey)
Mar-23-25 07:18AM	Wall Street Week Ahead (SeekingAlpha)
Mar-21-25 12:16PM	Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz (TipRanks) -13.63%
12:03PM	ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
03:03AM	ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
12:40AM	Q4 2024 ARS Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ERIC KARAS	Officer	Oct 30 '26	Proposed Sale	3.38	80,000	270,272		Oct 30 04:30 PM
ERIC KARAS	Officer	Oct 19 '26	Proposed Sale	4.10	100,000	410,240		Oct 19 04:22 PM
ERIC KARAS	Officer	Oct 01 '26	Proposed Sale	4.26	100,000	426,097		Oct 01 04:29 PM
ERIC KARAS	Officer	Sep 30 '26	Proposed Sale	4.32	100,000	431,560		Sep 30 04:29 PM
RICHARD LOWENTHAL	Officer	Sep 11 '26	Proposed Sale	5.06	35,000	176,995		Sep 11 04:18 PM
ERIC KARAS	Officer	Sep 11 '26	Proposed Sale	4.96	14,064	69,762		Sep 11 04:10 PM
RICHARD LOWENTHAL	Officer	Sep 04 '26	Proposed Sale	5.61	75,000	421,058		Sep 04 04:09 PM
RICHARD LOWENTHAL	Officer	Sep 03 '26	Proposed Sale	5.84	19,805	115,564		Sep 03 04:31 PM
RICHARD LOWENTHAL	Officer	Sep 02 '26	Proposed Sale	5.95	840	5,000		Sep 02 05:23 PM
SARINA TANIMOTO	Officer	Sep 01 '26	Proposed Sale	6.01	45,388	272,850		Sep 01 04:52 PM
SARINA TANIMOTO	Officer	Aug 31 '26	Proposed Sale	5.82	63,289	368,099		Aug 31 04:08 PM
SARINA TANIMOTO	Officer	Aug 20 '26	Proposed Sale	5.92	25,000	147,970		Aug 20 05:32 PM
RICHARD LOWENTHAL	Officer	Aug 20 '26	Proposed Sale	5.93	25,000	148,160		Aug 20 04:26 PM
SARINA TANIMOTO	Officer	Aug 19 '26	Proposed Sale	6.45	25,000	161,170		Aug 19 04:20 PM
RICHARD LOWENTHAL	Officer	Aug 19 '26	Proposed Sale	6.45	50,000	322,345		Aug 19 04:10 PM
SARINA TANIMOTO	Officer	Aug 18 '26	Proposed Sale	6.30	49,401	311,192		Aug 18 06:04 PM
RICHARD LOWENTHAL	Officer	Aug 18 '26	Proposed Sale	6.32	50,000	315,885		Aug 18 05:38 PM
Karas Eric	Chief Commercial Officer	Jun 12 '26	Option Exercise	1.50	25,000	37,500	37,176	Jun 12 08:06 PM
Karas Eric	Chief Commercial Officer	Jun 12 '26	Sale	10.00	25,000	250,000	12,176	Jun 12 08:06 PM
Fitzpatrick Alexander A	Chief Legal Officer	Jun 12 '26	Sale	10.00	3,355	33,550	90,910	Jun 12 08:04 PM
ERIC KARAS	Officer	Jun 12 '26	Proposed Sale	10.00	25,000	250,000		Jun 12 04:31 PM
ALEXANDER FITZPATRICK	Officer	Jun 12 '26	Proposed Sale	10.00	3,355	33,550		Jun 12 04:17 PM
Dorsey Brian	Chief Operating Officer	Nov 13 '25	Option Exercise	0.64	21,828	13,970	32,617	Nov 14 06:43 PM
Dorsey Brian	Chief Operating Officer	Nov 13 '25	Sale	8.71	21,828	190,050	10,789	Nov 14 06:43 PM
Chakma Justin	Chief Business Officer	Nov 12 '25	Option Exercise	0.84	30,000	25,200	166,380	Nov 14 06:42 PM
Chakma Justin	Chief Business Officer	Nov 12 '25	Sale	8.87	166,380	1,476,147	0	Nov 14 06:42 PM
BRIAN T DORSEY	Officer	Nov 13 '25	Proposed Sale	8.71	21,828	190,050		Nov 13 04:08 PM
JUSTIN CHAKMA	Officer	Nov 12 '25	Proposed Sale	8.91	30,000	267,357		Nov 12 05:26 PM
Chakma Justin	Officer	Nov 12 '25	Proposed Sale	8.87	138,380	1,227,420		Nov 12 10:56 AM

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

Chief Business OfficerMr. Justin Chakma

CEOMr. Donn Casale

Co-Founder & Chief Science OfficerDr. Robert Bell Ph.D.

Chief Financial OfficerMs. Kathleen D. Scott CPA

Chief Operating OfficerMr. Brian T. Dorsey M.S.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SPRY

ARS Pharmaceuticals Inc

Upgrade your Finviz experience